Clinical Trial

Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Efficacy and safety of Iparomlimab and Tuvonralimab in combination with lenvatinib and SOX chemotherapy in potentially resectable MSI-H, dMMR locally advanced gastric or gastroesophageal junction adenocarcinoma patients: A prospective, multicenter, open-label Phase II single-arm clinical trial
Trial Details
NCT Number NCT07151209
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 20 participants
Start Date 2025-09
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-03